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Abstract
Background: Recent evidence suggests that brain-derived neurotrophic factor (BDNF) is an
attractive candidate for modifying age at onset (AO) in Huntington disease (HD). In particular, the
functional Val66Met polymorphism appeared to exert a significant effect. Here we evaluate BDNF
variability with respect to AO of HD using markers that represent the entire locus.
Methods: Five selected tagging polymorphisms were genotyped across a 65 kb region comprising
the BDNF gene in a well established cohort of 250 unrelated German HD patients.
Results: Addition of BDNF genotype variations or one of the marker haplotypes to the effect of
CAG repeat lengths did not affect the variance of the AO.
Conclusion: We were unable to verify a recently reported association between the functional
Val66Met polymorphism in the BDNF gene and AO in HD. From our findings, we conclude that
neither sequence variations in nor near the gene contribute significantly to the variance of AO.
Background
Conclusive evidence indicates that brain-derived neuro-
trophic factor (BDNF) plays a pivotal role in the patho-
physiology of Huntington disease (HD). As the protein
huntingtin (htt) directly modulates the expression of neu-
ron-restrictive silencer factor (NRSF)-controlled genes,
wild type (wt) htt stimulates the production of BDNF,
whereas mutant htt causes the opposite effect [1]. It has
been shown recently in transgenic mice that BDNF has an
impact on the age at onset (AO) and the severity of motor
dysfunction by controlling survival of striatal projection
neurons [2].
The BDNF gene consists of five alternatively spliced 5'
exons and one major 3' exon producing at least six BDNF
transcripts leading to three pre-proprotein isoforms which
differ in the lengths of the signal peptides. Sequence vari-
ations in BDNF may therefore lead to variations in gene
expression or protein metabolism causing selective neuro-
nal vulnerability. The single nucleotide polymorphism
(SNP) rs6265, producing a valine-to-methionine substitu-
tion at codon 66 (Val66Met) in the human BDNF gene
appears to exert an effect on intracellular trafficking and
activity-dependent secretion of BDNF [3]. Furthermore,
Met-BDNF carriers demonstrate substantial relative
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decreases in hippocampal volume, and Val/Met-BDNF
affects the volume of gray matter in the cerebral neocortex
of normal humans. Finally Met-BDNF is associated with
volume reductions primarily in the lateral convexity of the
prefrontal cortex [4]. Thus, the Val66Met polymorphism
may be a modifying genetic factor in the expression of a
number of normal and abnormal brain conditions, and
therefore represents a good candidate gene for modifying
AO in HD. In this context, several associations between
BDNF polymorphisms and neurological and psychiatric
disorders have been reported [5]. In addition, a recent
study demonstrated that HD patients heterozygous for the
Val66Met polymorphism present a later AO than
homozygous carriers of Val-BDNF [6].
In this study, we investigated the relation between the
BDNF gene and the AO of HD using genetic markers that
represent the overall variability at this locus.
Methods
We selected tagging polymorphisms from the BDNF gene
(rs6265, rs11030104, rs7103873, rs2049046 and
rs12273363) based on HapMap data. We examined the
associations between BDNF polymorphisms and motor
AO of HD in 250 unrelated patients with clinical diagno-
sis of HD as recruited from the Huntington Center (HZ)
NRW, Bochum (Germany) [7]. Informed consent was
obtained and the institutional Ethics Committee of
Bochum Ruhr-University approved this study.
The expanded CAG repeats explained 50.9% of the vari-
ance in AO in this cohort. The potential influence of cer-
tain genotypes on AO was calculated by linear regression,
in which R2 illustrates the relative improvement of the
regression model when the various genotypes are consid-
ered in addition to the expanded CAG block in the hunt-
ingtin gene.
Relationship between BDNF Val66Met (rs6265) genotypes and age at onset (AO) for 250 Huntington disease patients Figure 1
Relationship between BDNF Val66Met (rs6265) genotypes and age at onset (AO) for 250 Huntington disease patients. For each 
genotype, the median AO is represented as a black bar, the quartile is shown as a solid box, and the range is indicated by the 
margins.
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Results and Discussion
LD analysis revealed strong LD between all neighboring
markers. Patients carrying different genotypes and haplo-
types, respectively, showed no differences in AO as evi-
denced in the box plot of Val66Met genotypes and AO
(figure 1). Addition of BDNF genotype variations or one
of the five marker haplotypes to the effect of CAG repeat
lengths resulted in no significant increase of the R2 value.
The same effect was evident in a sub-group of patients (n
= 194) with higher variance in AO (CAG repeat range 40–
45; R2 = 0.36). Observed frequencies for all five SNPs
(table 1) were in Hardy-Weinberg equilibrium. Our
results clearly indicate that genetic variations in the BDNF
gene do not influence the variance of AO in HD in Ger-
man patients in contrast to the results of Alberch and col-
laborators [6]. Several reasons may explain the
discrepancy between these results. The previously
reported association could have resulted from a type I
error. Possible selection bias due to admixture may have
been due to inclusion of DNA samples of relatives, the
exclusion of which has not fully been detailed in the
paper. Further evidence for such an assumption is implied
by the very low R2 (0.11) in the interval between 42 and
49 CAG repeats. Alternatively, true association could exist
only in groups of a specific ethnic origin and, presumably,
a similar genetic background. While this manuscript was
under review two other independent reports have been
published by two different groups leading to the same
conclusion indicating no association between the
Val66Met genotype and variation in AO [8,9], nor three
other BDNF SNPs [9].
Conclusion
In our association study between common polymor-
phisms that represent the entire variability of the BDNF
gene and the variance in motor AO in HD, we were unable
to verify the reported association between a single poly-
morphism at the BDNF gene and AO in HD.
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A
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AA
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AT
111(44.0)
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C
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